<?xml version="1.0" ?>
<TimeML xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://timeml.org/timeMLdocs/TimeML_1.2.1.xsd">

<DOCID>695197498476</DOCID>

<DCT><TIMEX3 tid="t0" type="DATE" value="20170129" temporalFunction="false" functionInDocument="CREATION_TIME">January 29, 2017</TIMEX3></DCT>

<TITLE>Team identifies tuberculosis drug and dose regimen that may cut time by up to 75 percent</TITLE>


<TEXT>
<EVENT eid="e1" class="STATE">Taking</EVENT> a new approach toward tuberculosis therapy, a UCLA <EVENT eid="e2" class="OCCURRENCE">led</EVENT> research team has <EVENT eid="e3" class="OCCURRENCE">devised</EVENT> a potential drug regimen that could <EVENT eid="e4" class="OCCURRENCE">cut</EVENT> the treatment time by up to 75 percent, while simultaneously <EVENT eid="e5" class="OCCURRENCE">reducing</EVENT> the risk that patients could <EVENT eid="e6" class="OCCURRENCE">develop</EVENT> drug resistant TB. 

To <EVENT eid="e7" class="OCCURRENCE">identify</EVENT> the regimen, the researchers <EVENT eid="e8" class="OCCURRENCE">launched</EVENT> a systematic <EVENT eid="e9" class="OCCURRENCE">search</EVENT> for an optimal drug treatment using the Parabolic Response Surface Platform, a data analysis method that identifies which drug combinations <EVENT eid="e10" class="OCCURRENCE">work</EVENT> synergistically—that is, with individual drugs <EVENT eid="e11" class="OCCURRENCE">working</EVENT> together in a way that is more potent than the sum of their individual potencies. 

The study, published in the peer <EVENT eid="e12" class="OCCURRENCE">reviewed</EVENT> journal Nature Communications, is the first to <EVENT eid="e13" class="OCCURRENCE">use</EVENT> the platform to <EVENT eid="e14" class="OCCURRENCE">identify</EVENT> more effective TB drug regimens and one of the first to <EVENT eid="e15" class="OCCURRENCE">focus</EVENT> on a communicable disease. 

TB is one of the world s deadliest diseases, <EVENT eid="e16" class="OCCURRENCE">killing</EVENT> more people than any other disease <EVENT eid="e17" class="OCCURRENCE">caused</EVENT> by a single infectious organism. Worldwide, about 10 million people <EVENT eid="e18" class="OCCURRENCE">develop</EVENT> active TB <TIMEX3 tid="t1" type="DURATION" value="PXY">each year</TIMEX3> and about 1.5 million people <EVENT eid="e19" class="OCCURRENCE">die</EVENT> of the disease, with India, Indonesia, China, Nigeria, Pakistan and South Africa <EVENT eid="e20" class="OCCURRENCE">accounting</EVENT> for 60 percent of the total, according to the World Health Organization. The United States <EVENT eid="e21" class="OCCURRENCE">saw</EVENT> 9,557 cases in <TIMEX3 tid="t2" type="DATE" value="2015">2015</TIMEX3> and, <EVENT eid="e22" class="REPORTING">according</EVENT> to the most recent data available, 493 deaths from the <EVENT eid="e23" class="OCCURRENCE">disease</EVENT> in <TIMEX3 tid="t3" type="DATE" value="2014">2014</TIMEX3>. More than 2 billion people have latent infections of the disease causing bacterium, Mycobacterium tuberculosis, <EVENT eid="e24" class="REPORTING">meaning</EVENT> they could ultimately <EVENT eid="e25" class="OCCURRENCE">develop</EVENT> active disease. 

The <TIMEX3 tid="t4" type="DATE" value="PRESENT_REF">current</TIMEX3> standard for treating TB is a four drug regimen that has been in use since <TIMEX3 tid="t5" type="DATE" value="198X">the 1980s</TIMEX3>. It was <EVENT eid="e26" class="OCCURRENCE">developed</EVENT> through trial and error, with physicians <EVENT eid="e27" class="OCCURRENCE">adding</EVENT> or substituting one drug at a time to existing regimens, rather than through a systematic <EVENT eid="e28" class="OCCURRENCE">search</EVENT> for synergistic drugs. 

The regimen is unusually onerous, <EVENT eid="e29" class="OCCURRENCE">requiring</EVENT> six to <TIMEX3 tid="t6" type="DURATION" value="P8M">eight months</TIMEX3> of therapy, <EVENT eid="e30" class="REPORTING">said</EVENT> Dr. Marcus Horwitz, Distinguished Professor of Medicine and Microbiology, Immunology  amp; Molecular Genetics at the David Geffen School of Medicine at UCLA and the study s senior author. 

 The lengthy course <EVENT eid="e31" class="OCCURRENCE">increases</EVENT> the likelihood of drug toxicity and often leads to poor patient adherence to the drug regimens, which in turn <EVENT eid="e32" class="OCCURRENCE">prompts</EVENT> the emergence of drug resistant TB,  he <EVENT eid="e33" class="REPORTING">said</EVENT>.  Drug resistant TB, which requires up <TIMEX3 tid="t7" type="DURATION" value="P2Y">to two years</TIMEX3> to <EVENT eid="e34" class="OCCURRENCE">treat</EVENT> with <TIMEX3 tid="t8" type="DATE" value="PRESENT_REF">current</TIMEX3> regimens, is <EVENT eid="e35" class="I_STATE">difficult</EVENT> to <EVENT eid="e36" class="OCCURRENCE">treat</EVENT> and <EVENT eid="e37" class="I_STATE">carries</EVENT> a high fatality rate.  

The PRS technology can be <EVENT eid="e38" class="OCCURRENCE">applied</EVENT> to any disease and has been <EVENT eid="e39" class="OCCURRENCE">used</EVENT> in oncology, infectious diseases, immunosuppression and other areas in both the lab and the clinic, <EVENT eid="e40" class="REPORTING">said</EVENT> Chih Ming Ho, Distinguished Research Professor of Mechanical and Aerospace Engineering at the UCLA Henry Samueli School of Engineering and Applied Science, and principal investigator of this study. 

 This <EVENT eid="e41" class="I_ACTION">makes</EVENT> it possible to <EVENT eid="e42" class="OCCURRENCE">identify</EVENT> the most effective drug and dose combinations to <EVENT eid="e43" class="OCCURRENCE">treat</EVENT> a disease by sampling a relatively small number of different drug dose combinations among billions of possible combinations,  Ho <EVENT eid="e44" class="REPORTING">said</EVENT>.  It greatly <EVENT eid="e45" class="OCCURRENCE">reduces</EVENT> the time and effort <EVENT eid="e46" class="OCCURRENCE">required</EVENT> to <EVENT eid="e47" class="OCCURRENCE">identify</EVENT> optimal drug combinations.  

In a previous study, the researchers <EVENT eid="e48" class="I_ACTION">assessed</EVENT> the effectiveness of about 500 combinations of drugs and doses <EVENT eid="e49" class="OCCURRENCE">using</EVENT> a cell culture model. That <EVENT eid="e50" class="I_ACTION">enabled</EVENT> them to <EVENT eid="e51" class="OCCURRENCE">identify</EVENT> several highly synergistic three  and four drug regimens that would likely be more <EVENT eid="e52" class="STATE">potent</EVENT> than the standard regimen <EVENT eid="e53" class="OCCURRENCE">used</EVENT> to <EVENT eid="e54" class="OCCURRENCE">treat</EVENT> TB. 

In the <TIMEX3 tid="t9" type="DATE" value="PRESENT_REF">current</TIMEX3> study, the researchers first <EVENT eid="e55" class="OCCURRENCE">used</EVENT> the parabolic response surface approach to <EVENT eid="e56" class="OCCURRENCE">determine</EVENT> the optimal drug doses in mice for each of four drugs in two combinations. They then <EVENT eid="e57" class="OCCURRENCE">tested</EVENT> those combinations—PRS Regimens I and II—in mice <EVENT eid="e58" class="OCCURRENCE">infected</EVENT> with a highly virulent strain of M. tuberculosis. The PRS I and II regimens <EVENT eid="e59" class="OCCURRENCE">killed</EVENT> TB bacteria in the lungs and <EVENT eid="e60" class="OCCURRENCE">cured</EVENT> the mice up to four times faster than the standard regimen. To <EVENT eid="e61" class="OCCURRENCE">verify</EVENT> whether the animals were <EVENT eid="e62" class="OCCURRENCE">cured</EVENT>, treatment was <EVENT eid="e63" class="OCCURRENCE">halted</EVENT> after various treatment periods, and when a <TIMEX3 tid="t10" type="DURATION" value="P3M">three month</TIMEX3> waiting time <EVENT eid="e64" class="OCCURRENCE">elapsed</EVENT>, confirmation was <EVENT eid="e65" class="I_ACTION">made</EVENT> that the mice had no TB bacteria in their lungs. 

If the new regimens are as successful in <EVENT eid="e66" class="OCCURRENCE">treating</EVENT> TB in humans as they <EVENT eid="e67" class="STATE">were</EVENT> in mice, the much more effective of the two regimens, PRS Regimen II, <EVENT eid="e68" class="OCCURRENCE">made</EVENT> up of the drugs clofazimine, bedaquiline, ethambutol and pyrazinamide, would <EVENT eid="e69" class="OCCURRENCE">reduce</EVENT> treatment time by 75 percent—from the <TIMEX3 tid="t11" type="DATE" value="X">six</TIMEX3> to <TIMEX3 tid="t12" type="DURATION" value="P8M">eight months</TIMEX3> <EVENT eid="e70" class="OCCURRENCE">required</EVENT> under the standard regimen to about <TIMEX3 tid="t13" type="DURATION" value="P6W">six weeks</TIMEX3> to <TIMEX3 tid="t14" type="DURATION" value="P2M">two months</TIMEX3>. 

 As a result, patients are more likely to <EVENT eid="e71" class="OCCURRENCE">adhere</EVENT> to the drug regimen, <EVENT eid="e72" class="OCCURRENCE">suffer</EVENT> less drug toxicity, and be less likely to <EVENT eid="e73" class="OCCURRENCE">develop</EVENT> drug resistant TB,  Horwitz <EVENT eid="e74" class="REPORTING">said</EVENT>.  The PRS regimens are also suitable for <EVENT eid="e75" class="OCCURRENCE">treating</EVENT> most cases of drug resistant TB because they do not <EVENT eid="e76" class="OCCURRENCE">contain</EVENT> the two drugs to which people with the drug resistant disease typically <EVENT eid="e77" class="OCCURRENCE">develop</EVENT> resistance. These cases are <EVENT eid="e78" class="I_STATE">anticipated</EVENT> to be <EVENT eid="e79" class="STATE">treatable</EVENT> as rapidly as drug sensitive cases with the PRS regimens,  he <EVENT eid="e80" class="REPORTING">added</EVENT>. 

The next step is to <EVENT eid="e81" class="OCCURRENCE">test</EVENT> the drug combinations in humans. A pilot study of PRS Regimen I has already <EVENT eid="e82" class="OCCURRENCE">begun</EVENT>; this regimen consists of generic drugs only, which was a requirement for this particular study. Preliminary results indicate that <TIMEX3 tid="t15" type="DURATION" value="P4M">four months</TIMEX3> of <EVENT eid="e83" class="OCCURRENCE">treating</EVENT> drug sensitive TB with this regimen would be at least as effective as <TIMEX3 tid="t16" type="DURATION" value="P6M">six months</TIMEX3> of treatment with the standard regimen. In addition, in laboratory studies, the researchers are <EVENT eid="e84" class="OCCURRENCE">using</EVENT> the PRS analysis against a larger number of TB drugs, including experimental drugs not yet <EVENT eid="e85" class="OCCURRENCE">approved</EVENT> for human use, to <EVENT eid="e86" class="I_ACTION">try</EVENT> to <EVENT eid="e87" class="OCCURRENCE">identify</EVENT> even more potent regimens. 

More information: Bai Yu Lee et al. Drug regimens <EVENT eid="e88" class="OCCURRENCE">identified</EVENT> and <EVENT eid="e89" class="OCCURRENCE">optimized</EVENT> by output <EVENT eid="e90" class="OCCURRENCE">driven</EVENT> platform markedly reduce tuberculosis treatment time, Nature Communications (<TIMEX3 tid="t17" type="DATE" value="2017">2017</TIMEX3>). DOI: 10.1038/ncomms14183 

Provided by: University of California, Los Angeles 

Explore further 

New drug combinations could significantly <EVENT eid="e91" class="OCCURRENCE">improve</EVENT> tuberculosis <EVENT eid="e92" class="OCCURRENCE">treatment</EVENT> 

<TIMEX3 tid="t18" type="DATE" value="2016-03-28">Mar 28, 2016</TIMEX3> 

Researchers from UCLA and Shanghai Jiao Tong University have <EVENT eid="e93" class="OCCURRENCE">made</EVENT> an important step toward a substantially faster and more effective treatment for tuberculosis, which infects some 10 million people and <EVENT eid="e94" class="OCCURRENCE">causes</EVENT> 1.5 million ... 

Expanded regimens associated with improved treatment response in MDR TB 

<TIMEX3 tid="t19" type="DATE" value="2015-12-29">Dec 29, 2015</TIMEX3> 

Treating multidrug resistant tuberculosis (MDR TB) with regimens that include a greater number of drugs may <EVENT eid="e95" class="OCCURRENCE">improve</EVENT> outcomes, and baseline drug susceptibility testing (DST) could <EVENT eid="e96" class="OCCURRENCE">identify</EVENT> drugs with the greatest likelihood ... 

Computer model <EVENT eid="e97" class="OCCURRENCE">predicts</EVENT> potential impact of short course therapy against multidrug resistant tuberculosis 

<TIMEX3 tid="t20" type="DATE" value="2016-12-15">Dec 15, 2016</TIMEX3> 

Johns Hopkins researchers have <EVENT eid="e98" class="OCCURRENCE">developed</EVENT> a computer simulation that <EVENT eid="e99" class="I_ACTION">helps</EVENT> predict under which circumstances a new short course treatment regimen for drug resistant tuberculosis could substantially <EVENT eid="e100" class="OCCURRENCE">reduce</EVENT> the global incidence ... 

WHO approves new, faster treatment for drug resistant TB 

<TIMEX3 tid="t21" type="DATE" value="2016-05-12">May 12, 2016</TIMEX3> 

The World Health Organization <EVENT eid="e101" class="OCCURRENCE">approved</EVENT> a new treatment for multi drug resistant tuberculosis (MDR TB) on <TIMEX3 tid="t22" type="DATE" value="2017-01-26">Thursday</TIMEX3>, a crucial step towards <EVENT eid="e102" class="OCCURRENCE">replacing</EVENT> an old, costly therapy that is brutal on patients and only 50 percent effective. 

Novel algorithm <EVENT eid="e103" class="I_ACTION">predicts</EVENT> drug combinations to <EVENT eid="e104" class="OCCURRENCE">treat</EVENT> drug resistant fungal infections 

<TIMEX3 tid="t23" type="DATE" value="2016-07-14">Jul 14, 2016</TIMEX3> 

Scientists have <EVENT eid="e105" class="OCCURRENCE">created</EVENT> an algorithm that can <EVENT eid="e106" class="OCCURRENCE">identify</EVENT> drug combinations to <EVENT eid="e107" class="OCCURRENCE">treat</EVENT> fungal infections that have <EVENT eid="e108" class="OCCURRENCE">become</EVENT> resistant to current drug <EVENT eid="e109" class="OCCURRENCE">treatments</EVENT>. This new study, <EVENT eid="e110" class="OCCURRENCE">published</EVENT> in PLOS Computational Biology, <EVENT eid="e111" class="REPORTING">represents</EVENT> ... 

TB Alliance launches  Nix TB  clinical trial to <EVENT eid="e112" class="OCCURRENCE">test</EVENT> new XDR TB treatment 

<TIMEX3 tid="t24" type="DATE" value="2015-05-14">May 14, 2015</TIMEX3> 

TB Alliance and its partners <EVENT eid="e113" class="OCCURRENCE">announced</EVENT> the <EVENT eid="e114" class="ASPECTUAL">start</EVENT> of a clinical trial of a new regimen to <EVENT eid="e115" class="OCCURRENCE">treat</EVENT> extensively drug resistant tuberculosis (XDR TB.) It is the first study to <EVENT eid="e116" class="OCCURRENCE">test</EVENT> an all oral drug regimen, <EVENT eid="e117" class="OCCURRENCE">comprised</EVENT> of drugs with ...
</TEXT>


<MAKEINSTANCE eiid="ie19" eventID="e19" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie18" eventID="e18" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie11" eventID="e11" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie10" eventID="e10" pos="UNKNOWN" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie13" eventID="e13" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie12" eventID="e12" pos="UNKNOWN" tense="PRESENT" aspect="PERFECTIVE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie15" eventID="e15" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie14" eventID="e14" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie17" eventID="e17" pos="VERB" tense="PASTPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie16" eventID="e16" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie91" eventID="e91" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="SHOULD" />
<MAKEINSTANCE eiid="ie90" eventID="e90" pos="VERB" tense="PAST" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie93" eventID="e93" pos="VERB" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie92" eventID="e92" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie95" eventID="e95" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="SHOULD" />
<MAKEINSTANCE eiid="ie94" eventID="e94" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie97" eventID="e97" pos="VERB" tense="PRESENT" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie96" eventID="e96" pos="VERB" tense="NONE" aspect="NONE" polarity="POS" modality="SHOULD" />
<MAKEINSTANCE eiid="ie99" eventID="e99" pos="UNKNOWN" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie98" eventID="e98" pos="VERB" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie86" eventID="e86" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie87" eventID="e87" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie84" eventID="e84" pos="VERB" tense="PRESENT" aspect="PROGRESSIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie85" eventID="e85" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie82" eventID="e82" pos="VERB" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie83" eventID="e83" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie80" eventID="e80" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie81" eventID="e81" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie88" eventID="e88" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie89" eventID="e89" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie79" eventID="e79" pos="ADJECTIVE" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie78" eventID="e78" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie73" eventID="e73" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie72" eventID="e72" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie71" eventID="e71" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie70" eventID="e70" pos="VERB" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie77" eventID="e77" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie76" eventID="e76" pos="VERB" tense="PRESENT" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie75" eventID="e75" pos="VERB" tense="NONE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie74" eventID="e74" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie108" eventID="e108" pos="UNKNOWN" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie109" eventID="e109" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie102" eventID="e102" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie103" eventID="e103" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie100" eventID="e100" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie101" eventID="e101" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie106" eventID="e106" pos="VERB" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie107" eventID="e107" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie104" eventID="e104" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie105" eventID="e105" pos="VERB" tense="PAST" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie9" eventID="e9" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie8" eventID="e8" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie5" eventID="e5" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie4" eventID="e4" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie7" eventID="e7" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie6" eventID="e6" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="COULD" />
<MAKEINSTANCE eiid="ie1" eventID="e1" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie3" eventID="e3" pos="VERB" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie2" eventID="e2" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie68" eventID="e68" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie69" eventID="e69" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie60" eventID="e60" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie61" eventID="e61" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie62" eventID="e62" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie63" eventID="e63" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie64" eventID="e64" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie65" eventID="e65" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie66" eventID="e66" pos="NOUN" tense="PRESPART" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie67" eventID="e67" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie59" eventID="e59" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie58" eventID="e58" pos="VERB" tense="PASTPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie55" eventID="e55" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie54" eventID="e54" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie57" eventID="e57" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie56" eventID="e56" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie51" eventID="e51" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie50" eventID="e50" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie53" eventID="e53" pos="VERB" tense="PASTPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie52" eventID="e52" pos="ADJECTIVE" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie42" eventID="e42" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie43" eventID="e43" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie40" eventID="e40" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie41" eventID="e41" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie46" eventID="e46" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie47" eventID="e47" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie44" eventID="e44" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie45" eventID="e45" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie48" eventID="e48" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie49" eventID="e49" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie115" eventID="e115" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie114" eventID="e114" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie117" eventID="e117" pos="VERB" tense="PASTPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie116" eventID="e116" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie111" eventID="e111" pos="VERB" tense="PRESENT" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie110" eventID="e110" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie113" eventID="e113" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie112" eventID="e112" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie37" eventID="e37" pos="UNKNOWN" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie36" eventID="e36" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie35" eventID="e35" pos="ADJECTIVE" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie34" eventID="e34" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie33" eventID="e33" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie32" eventID="e32" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie31" eventID="e31" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie30" eventID="e30" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie39" eventID="e39" pos="UNKNOWN" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie38" eventID="e38" pos="ADJECTIVE" tense="NONE" aspect="NONE" polarity="POS" modality="WOULD" />
<MAKEINSTANCE eiid="ie24" eventID="e24" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie25" eventID="e25" pos="UNKNOWN" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie26" eventID="e26" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie27" eventID="e27" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie20" eventID="e20" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie21" eventID="e21" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie22" eventID="e22" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie23" eventID="e23" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie28" eventID="e28" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie29" eventID="e29" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />

<TLINK lid="TL23" timeID="t22" relatedToEventInstance="ie101" relType="BEFORE" />
<TLINK lid="TL25" timeID="t23" relatedToEventInstance="ie104" relType="INCLUDES" />
<TLINK lid="TL3" eventInstanceID="ie98" relatedToEventInstance="ie95" relType="AFTER" />
<TLINK lid="TL2" eventInstanceID="ie97" relatedToEventInstance="ie96" relType="INCLUDES" />
<TLINK lid="TL1" eventInstanceID="ie90" relatedToEventInstance="ie89" relType="AFTER" />
<TLINK lid="TL0" eventInstanceID="ie90" relatedToEventInstance="ie88" relType="BEFORE" />
<TLINK lid="TL7" eventInstanceID="ie8" relatedToEventInstance="ie7" relType="SIMULTANEOUS" />
<TLINK lid="TL6" eventInstanceID="ie8" relatedToEventInstance="ie9" relType="BEGINS" />
<TLINK lid="TL5" eventInstanceID="ie70" relatedToTime="t12" relType="IS_INCLUDED" />
<TLINK lid="TL4" eventInstanceID="ie88" relatedToEventInstance="ie89" relType="SIMULTANEOUS" />
<TLINK lid="TL9" eventInstanceID="ie1" relatedToEventInstance="ie2" relType="SIMULTANEOUS" />
<TLINK lid="TL8" eventInstanceID="ie6" relatedToEventInstance="ie5" relType="AFTER" />
<TLINK lid="TL17" timeID="t2" relatedToEventInstance="ie21" relType="INCLUDES" />
<TLINK lid="TL16" timeID="t6" relatedToEventInstance="ie29" relType="INCLUDES" />
<TLINK lid="TL15" eventInstanceID="ie29" relatedToTime="t6" relType="BEGINS" />
<TLINK lid="TL14" eventInstanceID="ie35" relatedToEventInstance="ie37" relType="SIMULTANEOUS" />
<TLINK lid="TL13" eventInstanceID="ie55" relatedToEventInstance="ie56" relType="AFTER" />
<TLINK lid="TL12" eventInstanceID="ie59" relatedToEventInstance="ie60" relType="SIMULTANEOUS" />
<TLINK lid="TL11" eventInstanceID="ie64" relatedToEventInstance="ie65" relType="AFTER" />
<TLINK lid="TL10" eventInstanceID="ie2" relatedToEventInstance="ie1" relType="SIMULTANEOUS" />
<TLINK lid="TL19" timeID="t15" relatedToEventInstance="ie83" relType="INCLUDES" />
<TLINK lid="TL18" timeID="t3" relatedToEventInstance="ie23" relType="INCLUDES" />
<TLINK lid="TL22" timeID="t18" relatedToEventInstance="ie91" relType="INCLUDES" />
<TLINK lid="TL20" timeID="t10" relatedToEventInstance="ie64" relType="BEFORE" />
<TLINK lid="TL21" timeID="t12" relatedToEventInstance="ie70" relType="INCLUDES" />
<TLINK lid="TL26" timeID="t23" relatedToEventInstance="ie105" relType="INCLUDES" />
<TLINK lid="TL27" timeID="t24" relatedToEventInstance="ie112" relType="INCLUDES" />
<TLINK lid="TL24" timeID="t23" relatedToEventInstance="ie106" relType="INCLUDES" />
</TimeML>
